Albinterferon α-2b

A genetic fusion protein for the treatment of chronic hepatitis C

G. Mani Subramanian, Michele Fiscella, Araba Lamousé-Smith, Stefan Zeuzem, John G. McHutchison

Research output: Contribution to journalArticle

Abstract

Treatment regimens based on the use of interferon-α (IFN-α) remain the cornerstone of therapy for chronic hepatitis C virus infection, which affects nearly 170 million people worldwide. Treatment options include unmodified IFN-α given three times weekly or pegylated IFNs given once weekly. The albumin-fusion platform takes advantage of the long half-life of human albumin to provide a new treatment approach that allows the dosing frequency of IFN-α to be reduced in individuals with chronic hepatitis C. Albinterferon α-2b (alb-IFN), a recombinant polypeptide composed of IFN-α2b genetically fused to human albumin, has an extended half-life and early evidence indicates that it is efficacious and well tolerated. Pharmacodynamic modeling supports treatment with alb-IFN at 2- or 4-week intervals. Phase 3 registration trials are in progress. The albumin-fusion platform is currently being applied to other important bioactive peptides with short half-lives. These fusion proteins, which are at present in different phases of clinical development, might lead to improved therapies across a broad range of diseases.

Original languageEnglish (US)
Pages (from-to)1411-1419
Number of pages9
JournalNature Biotechnology
Volume25
Issue number12
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Interferons
Chronic Hepatitis C
Albumins
Fusion reactions
Proteins
Half-Life
Pharmacodynamics
Peptides
Polypeptides
Virus Diseases
Viruses
Hepacivirus
Therapeutics

ASJC Scopus subject areas

  • Microbiology

Cite this

Subramanian, G. M., Fiscella, M., Lamousé-Smith, A., Zeuzem, S., & McHutchison, J. G. (2007). Albinterferon α-2b: A genetic fusion protein for the treatment of chronic hepatitis C. Nature Biotechnology, 25(12), 1411-1419. https://doi.org/10.1038/nbt1364

Albinterferon α-2b : A genetic fusion protein for the treatment of chronic hepatitis C. / Subramanian, G. Mani; Fiscella, Michele; Lamousé-Smith, Araba; Zeuzem, Stefan; McHutchison, John G.

In: Nature Biotechnology, Vol. 25, No. 12, 12.2007, p. 1411-1419.

Research output: Contribution to journalArticle

Subramanian, GM, Fiscella, M, Lamousé-Smith, A, Zeuzem, S & McHutchison, JG 2007, 'Albinterferon α-2b: A genetic fusion protein for the treatment of chronic hepatitis C', Nature Biotechnology, vol. 25, no. 12, pp. 1411-1419. https://doi.org/10.1038/nbt1364
Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG. Albinterferon α-2b: A genetic fusion protein for the treatment of chronic hepatitis C. Nature Biotechnology. 2007 Dec;25(12):1411-1419. https://doi.org/10.1038/nbt1364
Subramanian, G. Mani ; Fiscella, Michele ; Lamousé-Smith, Araba ; Zeuzem, Stefan ; McHutchison, John G. / Albinterferon α-2b : A genetic fusion protein for the treatment of chronic hepatitis C. In: Nature Biotechnology. 2007 ; Vol. 25, No. 12. pp. 1411-1419.
@article{3e30766e017b4ce8b2f82aa39fdce8c4,
title = "Albinterferon α-2b: A genetic fusion protein for the treatment of chronic hepatitis C",
abstract = "Treatment regimens based on the use of interferon-α (IFN-α) remain the cornerstone of therapy for chronic hepatitis C virus infection, which affects nearly 170 million people worldwide. Treatment options include unmodified IFN-α given three times weekly or pegylated IFNs given once weekly. The albumin-fusion platform takes advantage of the long half-life of human albumin to provide a new treatment approach that allows the dosing frequency of IFN-α to be reduced in individuals with chronic hepatitis C. Albinterferon α-2b (alb-IFN), a recombinant polypeptide composed of IFN-α2b genetically fused to human albumin, has an extended half-life and early evidence indicates that it is efficacious and well tolerated. Pharmacodynamic modeling supports treatment with alb-IFN at 2- or 4-week intervals. Phase 3 registration trials are in progress. The albumin-fusion platform is currently being applied to other important bioactive peptides with short half-lives. These fusion proteins, which are at present in different phases of clinical development, might lead to improved therapies across a broad range of diseases.",
author = "Subramanian, {G. Mani} and Michele Fiscella and Araba Lamous{\'e}-Smith and Stefan Zeuzem and McHutchison, {John G.}",
year = "2007",
month = "12",
doi = "10.1038/nbt1364",
language = "English (US)",
volume = "25",
pages = "1411--1419",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Albinterferon α-2b

T2 - A genetic fusion protein for the treatment of chronic hepatitis C

AU - Subramanian, G. Mani

AU - Fiscella, Michele

AU - Lamousé-Smith, Araba

AU - Zeuzem, Stefan

AU - McHutchison, John G.

PY - 2007/12

Y1 - 2007/12

N2 - Treatment regimens based on the use of interferon-α (IFN-α) remain the cornerstone of therapy for chronic hepatitis C virus infection, which affects nearly 170 million people worldwide. Treatment options include unmodified IFN-α given three times weekly or pegylated IFNs given once weekly. The albumin-fusion platform takes advantage of the long half-life of human albumin to provide a new treatment approach that allows the dosing frequency of IFN-α to be reduced in individuals with chronic hepatitis C. Albinterferon α-2b (alb-IFN), a recombinant polypeptide composed of IFN-α2b genetically fused to human albumin, has an extended half-life and early evidence indicates that it is efficacious and well tolerated. Pharmacodynamic modeling supports treatment with alb-IFN at 2- or 4-week intervals. Phase 3 registration trials are in progress. The albumin-fusion platform is currently being applied to other important bioactive peptides with short half-lives. These fusion proteins, which are at present in different phases of clinical development, might lead to improved therapies across a broad range of diseases.

AB - Treatment regimens based on the use of interferon-α (IFN-α) remain the cornerstone of therapy for chronic hepatitis C virus infection, which affects nearly 170 million people worldwide. Treatment options include unmodified IFN-α given three times weekly or pegylated IFNs given once weekly. The albumin-fusion platform takes advantage of the long half-life of human albumin to provide a new treatment approach that allows the dosing frequency of IFN-α to be reduced in individuals with chronic hepatitis C. Albinterferon α-2b (alb-IFN), a recombinant polypeptide composed of IFN-α2b genetically fused to human albumin, has an extended half-life and early evidence indicates that it is efficacious and well tolerated. Pharmacodynamic modeling supports treatment with alb-IFN at 2- or 4-week intervals. Phase 3 registration trials are in progress. The albumin-fusion platform is currently being applied to other important bioactive peptides with short half-lives. These fusion proteins, which are at present in different phases of clinical development, might lead to improved therapies across a broad range of diseases.

UR - http://www.scopus.com/inward/record.url?scp=36849040529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849040529&partnerID=8YFLogxK

U2 - 10.1038/nbt1364

DO - 10.1038/nbt1364

M3 - Article

VL - 25

SP - 1411

EP - 1419

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 12

ER -